Subscribe

Value Propositions

Osteoporosis is recognized as a growing problem in Europe. Approximately 3.5 million fragility fractures occur annually in the European Union. In 2010, fragility fractures cost €37 billion and were responsible for 43,000 deaths.
The 2012 American College of Rheumatology Guidelines for Management of Gout recommends xanthine oxidase inhibitor therapy with allopurinol or febuxostat as urate-lowering therapy (ULT) in the treatment of gout. By design, the guidelines do not address cost-effectiveness.
With data from the Humana commercial claims database, researchers evaluated the use and annual costs of biologic agents in the treatment of several autoimmune diseases.
  • Medicare Begins Coverage of Lung Cancer Screening with Low-Dose Computed Tomography for High-Risk Beneficiaries
  • NIH Awards $1.08 Million for Breast Cancer Research Using Genomic Sequencing and Computer Modeling to Investigate the Underlying Mechanism of Human Diseases
  • Northwestern Onco-SET Introduces Genomics-­Based, Personalized Medicine to All Patients with Cancer
  • Hematologic Drugs Offer Value Despite High Costs
There are a limited number of effective treatments available for knee osteoarthritis (OA), which has led to more than $185 billion in annual healthcare costs in the United States.
To identify a clear method of assessing remission in patients with rheumatoid arthritis (RA), investigators conducted a systematic review of the literature and found that ultrasounds may be more effective than clinical examination.
  • Immunotherapy Vaccine for Patients with Newly Diagnosed Glioblastoma Shows Promising Results
  • High Immunologic Response Seen with Oral Vaccine for Pancreatic Cancer in a Phase 1 Extension Trial
  • M.D. Anderson Cancer Center Launches New Programs After FDA’s Approval of Novel HPV Vaccine
The WHO’s International Agency for Research on Cancer Issued 12 Steps to Prevent Cancer
New Molecular Tests for Identifying Resistance to Bruton’s Tyrosine Kinase Inhibition in Patients with Chronic Lymphocytic Leukemia or Lymphoma-Related Mutations
Anticancer Drugs and Vaccines Have High Value for PhRMA, with First Place in the Current Pipeline
Value propositions from the October 2014 issue of Value-Based Care in Rheumatology.
Medicare Begins Coverage of Only FDA-Approved Noninvasive Stool DNA Test for Colorectal Cancer
NCI Launches Study of Exceptional Responders to Cancer Therapies: A New Phase in Precision Medicine?
New Collaboration on Novel Immunotherapy Vaccine May Revolutionize Lung Cancer Treatment
Mechanism of Action of Low-Dose Aspirin in Reducing Cancer Mortality Identified
Page 5 of 21
Results 41 - 50 of 206
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology